3
Total investments
0
Early stage
0
Mid stage
0
Late stage
13y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
2013
SpeechVive is a medical device company providing a communication solution for people with Parkinson's Disease. SpeechVive’s mission is to improve the quality of communication for people with Parkinson’s disease by empowering care partners and clinicians with technologies and support to restore one’s ability to communicate.
Experience · 9 entries
All (9)
Investments (3)
Board (3)
2022
Investment Advisory Board Member
Oct 2022
Wexford Science & Technology is a real estate company exclusively focused on partnering with universities, academic medical centers and research companies to develop vibrant, mixed-use, amenity-rich communities. Wexford’s Knowledge Communities are built on a foundation of discovery, innovation, entrepreneurial activity, corporate engagement, and community inclusion that creates visible outcomes in the form of substantial economic growth, new and diverse jobs, and community transformation.
2020
Portfolio Executive - RADx
Jun 2020
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research.
Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery.
Whether you are graduating with a bachelors degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career.
When you join us, you’re not just advancing your career — you’re driving the health of our country forward.
Official LinkedIn Account of the NIH.
Privacy policy: http://go.usa.gov/x9svN
Comment policy: https://bit.ly/3G6xq94
Engagement ≠ endorsement
2018
Managing Partner
Jan 2018
The LaunchPort™ is a Medical Device Venture Center and ISO-13485 Contract Manufacturing operation in Baltimore, Maryland that allows Medtech start-ups and emerging technology developers the ability to co-locate at an experienced, regulated manufacturing center. As part of that Residency, they are allowed to tap into core services at the site (e.g., financial operating systems, quality system development and management protocols & templates, logistics and purchasing support, regulatory compliance development, clinical trial, and post-market Device History File management), while utilizing their capital resources on developing their critical core competencies under the tutelage of an experienced Medtech operation.
The Venture Center operates like a medical device pilot plant, where Residents can develop different elements of their GMP process on a scale that is both capital efficient and can leverage core capabilities at the site. LaunchPort seeks to not only support the success of the management teams themselves, but de-risk the entities for both investors and future partners/acquirers.
The facility occupies approximately 25,000 square feet of assembly, engineering, clean room, and office space in the Port Covington economic development zone of Baltimore (https://pc.city/) and serves as a home base for the Residents. Port Covington is approximately equidistant from the Johns Hopkins and University of Maryland Medical Centers.
LaunchPort’s current Residents include those in the fields of Cardiology, General Surgery, Hemodialysis, In-Vitro Diagnostics, Gastroenterology, Neurology, Neurosurgery, Ophthalmology, Pulmonology, Robotics, and Tissue Engineering.
LaunchPort, LLC operates in four business areas – Ventures, Manufacturing, Service & Supply Chain, and Consulting/Programs.
2014
National Faculty, I-Corps
Jul 2014
The U.S. National Science Foundation (NSF) is an independent federal agency created by Congress in 1950 "to promote the progress of science; to advance the national health, prosperity, and welfare; to secure the national defense…" With an annual budget of more than $8 billion, NSF is the funding source for approximately 20 percent of all federally supported basic research conducted by America’s colleges and universities. In many fields, such as mathematics, computer science, and the social sciences, NSF is the major source of federal backing.
NSF awards about 11,000 new awards per year, with an average duration of three years -- to fund specific research proposals that have been judged the most promising by a rigorous and objective merit-review system. In the past few decades, NSF-funded researchers have won more than 200 Nobel Prizes as well as other honors too numerous to list. NSF funds equipment that is needed by scientists and engineers but is often too expensive for any one group or researcher to afford. Another essential element in NSFs mission is support for science and engineering education, from pre-K through graduate school and beyond.
There are many exciting careers at NSF, not only in science, technology, education and mathematics (STEM), but also in business and operations. For more information, please visit us at http://nsf.gov/careers/.
NSF welcomes opportunities to engage with you on our LinkedIn page. Please see our Comment Policy [http://www.nsf.gov/social/policies.jsp ] for more information.
2013
Board Member
2013
SpeechVive is a medical device company providing a communication solution for people with Parkinson's Disease. SpeechVive’s mission is to improve the quality of communication for people with Parkinson’s disease by empowering care partners and clinicians with technologies and support to restore one’s ability to communicate.
Show all 9 entries ↓
Similar investors
Construction investors in United States
Investor lists
Lists that match Robert's portfolio
- Construction investors in United States844 investors
- Wellness investors in United States2,620 investors
- Startup investors in United States6,245 investors






